JP6095072B2 - アミロイド病およびシヌクレイノパチーの処置のためのカフェイン含有化合物および組成物 - Google Patents
アミロイド病およびシヌクレイノパチーの処置のためのカフェイン含有化合物および組成物 Download PDFInfo
- Publication number
- JP6095072B2 JP6095072B2 JP2014538819A JP2014538819A JP6095072B2 JP 6095072 B2 JP6095072 B2 JP 6095072B2 JP 2014538819 A JP2014538819 A JP 2014538819A JP 2014538819 A JP2014538819 A JP 2014538819A JP 6095072 B2 JP6095072 B2 JP 6095072B2
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- amyloid
- compounds
- synuclein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *[n]1c(C(N(*)C(N2*)=O)=O)c2nc1 Chemical compound *[n]1c(C(N(*)C(N2*)=O)=O)c2nc1 0.000 description 1
- QTEQVEJOXGBDGI-UHFFFAOYSA-N CN(c1c(C(N2)=O)[nH]c(Br)n1)C2=O Chemical compound CN(c1c(C(N2)=O)[nH]c(Br)n1)C2=O QTEQVEJOXGBDGI-UHFFFAOYSA-N 0.000 description 1
- YRLRORFORQUTKS-UHFFFAOYSA-N C[n]1c(Br)nc(N(C)C(N2C)=O)c1C2=O Chemical compound C[n]1c(Br)nc(N(C)C(N2C)=O)c1C2=O YRLRORFORQUTKS-UHFFFAOYSA-N 0.000 description 1
- ZQYAQGCWSWESIX-UHFFFAOYSA-N O=C(c(cc1)cc(OCc2ccccc2)c1OCc1ccccc1)OCc1ccccc1 Chemical compound O=C(c(cc1)cc(OCc2ccccc2)c1OCc1ccccc1)OCc1ccccc1 ZQYAQGCWSWESIX-UHFFFAOYSA-N 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N OC(c(cc1)cc(O)c1O)=O Chemical compound OC(c(cc1)cc(O)c1O)=O YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552077P | 2011-10-27 | 2011-10-27 | |
| US61/552,077 | 2011-10-27 | ||
| PCT/US2012/059481 WO2013062762A1 (en) | 2011-10-27 | 2012-10-10 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532643A JP2014532643A (ja) | 2014-12-08 |
| JP2014532643A5 JP2014532643A5 (https=) | 2015-12-03 |
| JP6095072B2 true JP6095072B2 (ja) | 2017-03-15 |
Family
ID=48168320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538819A Expired - Fee Related JP6095072B2 (ja) | 2011-10-27 | 2012-10-10 | アミロイド病およびシヌクレイノパチーの処置のためのカフェイン含有化合物および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9169255B2 (https=) |
| EP (1) | EP2753333B1 (https=) |
| JP (1) | JP6095072B2 (https=) |
| CN (1) | CN104010641B (https=) |
| AU (1) | AU2012329274B2 (https=) |
| CA (1) | CA2853633A1 (https=) |
| WO (1) | WO2013062762A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001371B (zh) * | 2014-10-09 | 2019-07-05 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| NZ746901A (en) * | 2016-03-11 | 2023-06-30 | Ac Immune Sa | Bicyclic compounds for diagnosis and therapy |
| IL269550B2 (en) | 2017-03-27 | 2025-01-01 | Chase Therapeutics Corp | Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| CN113573708A (zh) * | 2019-02-07 | 2021-10-29 | 阿尔萨泰克公司 | 艾莫西平多价衍生物 |
| WO2023023867A1 (en) * | 2021-08-26 | 2023-03-02 | Mcmaster University | Compounds for reducing cholesterol and treating liver and kidney disease |
| CN115997722A (zh) * | 2022-12-26 | 2023-04-25 | 海南大学 | Aβ42-hIAPP共寡聚化物诱导的AD非人灵长类动物模型方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000069464A1 (en) * | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| EP1808169B8 (en) * | 1999-12-30 | 2012-07-04 | Proteotech Inc. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| DK1444233T3 (da) * | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| PT2527315E (pt) | 2002-05-31 | 2014-06-24 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
| CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
-
2012
- 2012-10-10 CA CA2853633A patent/CA2853633A1/en not_active Abandoned
- 2012-10-10 WO PCT/US2012/059481 patent/WO2013062762A1/en not_active Ceased
- 2012-10-10 AU AU2012329274A patent/AU2012329274B2/en not_active Ceased
- 2012-10-10 US US14/238,755 patent/US9169255B2/en not_active Expired - Fee Related
- 2012-10-10 CN CN201280051004.1A patent/CN104010641B/zh not_active Expired - Fee Related
- 2012-10-10 JP JP2014538819A patent/JP6095072B2/ja not_active Expired - Fee Related
- 2012-10-10 EP EP12842836.4A patent/EP2753333B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP2753333B1 (en) | 2017-06-21 |
| CN104010641B (zh) | 2017-04-12 |
| NZ623046A (en) | 2015-12-24 |
| AU2012329274B2 (en) | 2016-11-10 |
| WO2013062762A1 (en) | 2013-05-02 |
| JP2014532643A (ja) | 2014-12-08 |
| CN104010641A (zh) | 2014-08-27 |
| US9169255B2 (en) | 2015-10-27 |
| AU2012329274A1 (en) | 2014-04-17 |
| EP2753333A1 (en) | 2014-07-16 |
| EP2753333A4 (en) | 2015-01-28 |
| US20140194447A1 (en) | 2014-07-10 |
| CA2853633A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6095072B2 (ja) | アミロイド病およびシヌクレイノパチーの処置のためのカフェイン含有化合物および組成物 | |
| JP5431485B2 (ja) | β−アミロイド疾患およびシヌクレイノパチーを処置するための化合物、組成物、および方法 | |
| US7919530B2 (en) | Compounds, compositions, and methods for the treatment of synucleinopathies | |
| CN114341103B (zh) | 作为可用来治疗神经疾病的逆运体稳定剂的氨基胍腙 | |
| US8455687B2 (en) | Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies | |
| EP3437640B1 (en) | Agent for treating synucleinopathy | |
| US8916598B2 (en) | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies | |
| NZ623046B2 (en) | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | |
| US20100331380A1 (en) | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | |
| US9469605B2 (en) | Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies | |
| JP2021520412A (ja) | タンパク質ミスフォールディング疾患のための療法 | |
| US20150038591A1 (en) | Compounds, compositions and methods for the treatment of tauopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151009 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151009 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160517 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160519 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160816 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6095072 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |